<?xml version="1.0" encoding="UTF-8"?>
<p>Cholinesterase inhibitors (ChEIs) have recently become the most widely used drugs for the management of Alzheimer's disease (AD) [
 <xref rid="B54" ref-type="bibr">54</xref>]. ChEIs play a crucial role in the memory enhancement of AD patients through increasing ACh concentration in neural synaptic clefts and thus improving the brain cholinergic transmission and decreasing 
 <italic>β</italic>-amyloid aggregation and neurotoxic ﬁbrils formation [
 <xref rid="B55" ref-type="bibr">55</xref>–
 <xref rid="B57" ref-type="bibr">57</xref>]. However, synthetic AChEIs including galanthamine and tacrine have restrictions owing to the short half-life and adverse side effects such as digestive disorders, nausea, and dizziness [
 <xref rid="B58" ref-type="bibr">58</xref>, 
 <xref rid="B59" ref-type="bibr">59</xref>]. Hence, it is necessary to explore new safe alternatives with superior characteristics to deal with AD.
</p>
